The Pharmacy Times® Hematology Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of blood disorders, include blood and bone marrow cancers, anemia, hemophilia, blood-clotting disorders, and leukemia.
March 17th 2023
At 1 year, patients receiving chemotherapy regimens containing anthracyclines for lymphoma who took statins had an average ejection fraction that was 1.3% higher than those who took placebo.
FDA Approves First-in-Class Factor VIII Therapy for Hemophilia AFebruary 24th 2023
Altuviiio [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl; Sanofi] is high-sustained factor VIII replacement therapy indicated for routine prophylaxis and on-demand treatment to control bleeding episodes and for perioperative management in adults and children with hemophilia A.
FDA Grants Priority Review to Elranatamab for Relapsed/Refractory Multiple MyelomaFebruary 23rd 2023
Elranatamab is an investigational B-cell maturation antigen CD3-targeted bispecific antibody that may become the next standard of care for multiple myeloma, according to researchers.
Phase 3 Trial of Ciltacabtagene Autoleucel Meets Primary Endpoint in Relapsed, Refractory Multiple MyelomaFebruary 2nd 2023
The trial is the first randomized phase 3 study evaluating the efficacy and safety of ciltacabtagene autoleucel patients with relapsed and lenalidomide-refractory multiple myeloma.
Coexisting Hemophagocytic Lymphohistiocytosis, Clostridium difficile Complicates DiagnosisJanuary 31st 2023
Investigators emphasize the importance of a timely HLH diagnosis and prompt initiation of treatment, as well as close outpatient follow-up to increase patient survival.
Trial of Lisocabtagene Maraleucel Meets Primary Endpoint in Relapsed, Refractory Chronic Lymphocytic LeukemiaJanuary 31st 2023
Lisocabtagene maraleucel is a CD19-directed CAR T-cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells.
Commonly Overlooked Adverse Effects in the Community, Clinical Pharmacy Settings
Although pharmacists possess a wealth of knowledge on AEs, it remains a monumental task to recall the clinical significance of every AE, even with the most commonly used medications.
Study: Imbruvica for CLL Is Less Likely to Lead to Next-Line Treatment Than AcalabrutinibDecember 23rd 2022
Results show possible impact of using Janssen Pharmaceuticals’ ibrutinib in the front-line setting, providing additional data on chronic lymphocytic leukemia therapies.
Ponatinib Meets Primary Endpoint of Superior Function for Newly-Diagnosed Ph+ Acute Lymphoblastic LeukemiaDecember 15th 2022
Ponatinib could be the first targeted treatment approved in the United States for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Expert: More Effective Graft-versus-host Disease Prevention Strategies Could Provide ‘Real Cost Savings to the Health Care System’December 13th 2022
Richard T. Maziarz, MD, and a team of investigators assessed average medical costs of allo-HCT throughout a patient’s lifetime and the net monetary savings and value associated with reducing complications.
Ivosedinib Plus Azacytidine Provides Additional Treatment Option for Patients With AML, IDH1 Mutation DetectedDecember 13th 2022
The FDA clinical reviewer responsible for the approval of this combination therapy discusses the data that led to the approval in May 2022.